Capricor Therapeutics Inc (CAPR) - Net Assets
Based on the latest financial reports, Capricor Therapeutics Inc (CAPR) has net assets worth $305.79 Million USD as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($355.95 Million) and total liabilities ($50.16 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check CAPR asset liquidity ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $305.79 Million |
| % of Total Assets | 85.91% |
| Annual Growth Rate | N/A |
| 5-Year Change | 874.85% |
| 10-Year Change | N/A |
| Growth Volatility | 207.31 |
Capricor Therapeutics Inc - Net Assets Trend (1999–2025)
This chart illustrates how Capricor Therapeutics Inc's net assets have evolved over time, based on quarterly financial data. Also explore how large is Capricor Therapeutics Inc's balance sheet for the complete picture of this company's asset base.
Annual Net Assets for Capricor Therapeutics Inc (1999–2025)
The table below shows the annual net assets of Capricor Therapeutics Inc from 1999 to 2025. For live valuation and market cap data, see CAPR market cap overview.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $305.79 Million | +110.22% |
| 2024-12-31 | $145.46 Million | +543.60% |
| 2023-12-31 | $22.60 Million | +91.76% |
| 2022-12-31 | $11.79 Million | -62.43% |
| 2021-12-31 | $31.37 Million | +11.23% |
| 2020-12-31 | $28.20 Million | +312.31% |
| 2019-12-31 | $6.84 Million | +48.18% |
| 2018-12-31 | $4.62 Million | -58.89% |
| 2017-12-31 | $11.23 Million | +380.45% |
| 2016-12-31 | $-4.00 Million | -287.99% |
| 2015-12-31 | $-1.03 Million | +83.49% |
| 2014-12-31 | $-6.25 Million | -1068.24% |
| 2013-12-31 | $-534.88K | -110.93% |
| 2012-12-31 | $4.89 Million | +489.18% |
| 2011-12-31 | $830.72K | -68.01% |
| 2010-12-31 | $2.60 Million | -12.92% |
| 2009-12-31 | $2.98 Million | -41.57% |
| 2008-12-31 | $5.10 Million | -66.42% |
| 2007-12-31 | $15.20 Million | +11740.50% |
| 2006-12-31 | $-130.58K | -68.22% |
| 2005-12-31 | $-77.62K | -32.10% |
| 2004-12-31 | $-58.76K | -44.43% |
| 2003-12-31 | $-40.69K | -65.87% |
| 2002-12-31 | $-24.53K | -174.31% |
| 2001-12-31 | $-8.94K | -166.93% |
| 2000-12-31 | $13.36K | +2265.48% |
| 1999-12-31 | $-617.00 | -- |
Equity Component Analysis
This analysis shows how different components contribute to Capricor Therapeutics Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 30487776800.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $57.37K | 0.02% |
| Other Comprehensive Income | $283.15K | 0.09% |
| Other Components | $610.33 Million | 199.59% |
| Total Equity | $305.79 Million | 100.00% |
Capricor Therapeutics Inc Competitors by Market Cap
The table below lists competitors of Capricor Therapeutics Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Enliven Therapeutics Inc.
NASDAQ:ELVN
|
$1.78 Billion |
|
ONESPAWORLD HLDGS DL-0001
F:ORW
|
$1.78 Billion |
|
Guangzhou Fangbang Electronics Co Ltd
SHG:688020
|
$1.78 Billion |
|
Henan Huanghe Whirlwind Co Ltd
SHG:600172
|
$1.78 Billion |
|
Tootsie Roll Industries Inc
NYSE:TR
|
$1.78 Billion |
|
Yelp Inc
NYSE:YELP
|
$1.78 Billion |
|
Jiangsu Cai Qin Technology Co Ltd
SHG:688182
|
$1.78 Billion |
|
Fulltech Fiber Glass
TWO:1815
|
$1.78 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Capricor Therapeutics Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 145,462,336 to 305,792,145, a change of 160,329,809 (110.2%).
- Net loss of 105,043,946 reduced equity.
- New share issuances of 237,033,938 increased equity.
- Other comprehensive income decreased equity by 743,801.
- Other factors increased equity by 29,083,618.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-105.04 Million | -34.35% |
| Share Issuances | $237.03 Million | +77.51% |
| Other Comprehensive Income | $-743.80K | -0.24% |
| Other Changes | $29.08 Million | +9.51% |
| Total Change | $- | 110.22% |
Book Value vs Market Value Analysis
This analysis compares Capricor Therapeutics Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 4.70x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1999-12-31 | $-0.45 | $30.91 | x |
| 2000-12-31 | $9.72 | $30.91 | x |
| 2001-12-31 | $-5.92 | $30.91 | x |
| 2002-12-31 | $-16.24 | $30.91 | x |
| 2003-12-31 | $-26.94 | $30.91 | x |
| 2004-12-31 | $-38.92 | $30.91 | x |
| 2005-12-31 | $-51.41 | $30.91 | x |
| 2006-12-31 | $-4.89 | $30.91 | x |
| 2007-12-31 | $448.59 | $30.91 | x |
| 2008-12-31 | $105.77 | $30.91 | x |
| 2009-12-31 | $58.55 | $30.91 | x |
| 2010-12-31 | $40.36 | $30.91 | x |
| 2011-12-31 | $11.13 | $30.91 | x |
| 2012-12-31 | $57.99 | $30.91 | x |
| 2013-12-31 | $-0.51 | $30.91 | x |
| 2014-12-31 | $-5.34 | $30.91 | x |
| 2015-12-31 | $-0.65 | $30.91 | x |
| 2016-12-31 | $-2.16 | $30.91 | x |
| 2017-12-31 | $4.19 | $30.91 | x |
| 2018-12-31 | $1.57 | $30.91 | x |
| 2019-12-31 | $1.84 | $30.91 | x |
| 2020-12-31 | $1.81 | $30.91 | x |
| 2021-12-31 | $1.36 | $30.91 | x |
| 2022-12-31 | $0.48 | $30.91 | x |
| 2023-12-31 | $0.84 | $30.91 | x |
| 2024-12-31 | $4.13 | $30.91 | x |
| 2025-12-31 | $6.58 | $30.91 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Capricor Therapeutics Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -34.35%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.16x
- Recent ROE (-34.35%) is above the historical average (-98.51%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1999 | 0.00% | 0.00% | 0.00x | 0.00x | $-138.30 |
| 2000 | -273.35% | 0.00% | 0.00x | 1.07x | $-37.86K |
| 2001 | 0.00% | 0.00% | 0.00x | 0.00x | $-21.41K |
| 2002 | 0.00% | -135.73% | 459.36x | 0.00x | $-13.13K |
| 2003 | 0.00% | -739.79% | 2.02x | 0.00x | $-12.09K |
| 2004 | 0.00% | 0.00% | 0.00x | 0.00x | $-12.20K |
| 2005 | 0.00% | 0.00% | 0.00x | 0.00x | $-11.10K |
| 2006 | 0.00% | -16.11% | 90.68x | 0.00x | $-47.88K |
| 2007 | -67.78% | -10160.75% | 0.01x | 1.12x | $-11.82 Million |
| 2008 | -257.31% | 0.00% | 0.00x | 1.26x | $-13.64 Million |
| 2009 | -263.97% | 0.00% | 0.00x | 1.21x | $-8.17 Million |
| 2010 | -232.24% | 0.00% | 0.00x | 1.41x | $-6.29 Million |
| 2011 | -588.04% | -360.52% | 0.99x | 1.65x | $-4.97 Million |
| 2012 | -38.68% | -968.29% | 0.04x | 1.11x | $-2.38 Million |
| 2013 | 0.00% | -1766.97% | 0.09x | 0.00x | $-8.84 Million |
| 2014 | 0.00% | -149.20% | 0.31x | 0.00x | $-5.59 Million |
| 2015 | 0.00% | -340.50% | 0.23x | 0.00x | $-12.75 Million |
| 2016 | 0.00% | -589.53% | 0.17x | 0.00x | $-18.41 Million |
| 2017 | 21.66% | 177.84% | 0.08x | 1.45x | $1.31 Million |
| 2018 | -329.13% | -908.91% | 0.18x | 2.00x | $-15.65 Million |
| 2019 | -111.73% | -760.36% | 0.09x | 1.62x | $-8.33 Million |
| 2020 | -48.43% | -4401.94% | 0.01x | 1.23x | $-16.48 Million |
| 2021 | -63.83% | -8175.86% | 0.01x | 1.32x | $-23.16 Million |
| 2022 | -246.22% | -1137.37% | 0.05x | 4.25x | $-30.20 Million |
| 2023 | -98.61% | -88.52% | 0.43x | 2.60x | $-24.55 Million |
| 2024 | -27.82% | -181.71% | 0.13x | 1.17x | $-55.01 Million |
| 2025 | -34.35% | 0.00% | 0.00x | 1.16x | $-135.62 Million |
Industry Comparison
This section compares Capricor Therapeutics Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $44,828,400
- Average return on equity (ROE) among peers: -124.18%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Capricor Therapeutics Inc (CAPR) | $305.79 Million | 0.00% | 0.16x | $1.78 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $118.88 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $1.07 Billion |
| Abeona Therapeutics Inc (ABEO) | $3.60 Million | -91.89% | 0.28x | $292.09 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $171.87 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $448.19K |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $345.85 Million |
| Arbutus Biopharma Corp (ABUS) | $88.00 Million | -44.09% | 0.34x | $840.56 Million |
| ABVC Biopharma Inc (ABVC) | $80.00K | -31.70% | 0.38x | $26.41 Million |
| Abivax SA American Depositary Shares (ABVX) | $40.58 Million | -434.26% | 4.06x | $9.33 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $23.36 Million | -97.44% | 0.37x | $3.74 Billion |
About Capricor Therapeutics Inc
Capricor Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States. Its lead product candidate is the Deramiocel, an allogeneic cardiosphere-derived cells, which is in phase 3 clinical trial for the treat… Read more